Sells it“We have developed an integrated, end-to-end autologous iPSC platform designed to generate autologous cell therapies for the treatment of neurodegenerative diseases (our platform).”
In development“Capricor is a clinical-stage biotechnology company developing cell- and exosome-based therapies, including Deramiocel for Duchenne muscular dystrophy (DMD).”
Latest 10-QQ3 FY2026NegativeRestructuring ·
Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.
Sells it 4%, $354.0M a quarter“CAR T therapies Yescarta and Tecartus depend on reliable patient-specific cell engineering, conditioning medicines, side-effect treatments, and a complex network of collection centers, vendors, hospitals, and shipping.”
Latest 10-QQ3 FY2026Impairment / charge ·
Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.